Get the app
US › Healthcare

Cue Biopharma (CUE)

US · Healthcare · Biotechnology

$16.71-10.50%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$7.9M
Revenue YoY
+166.7%
Net profit
$-153.1M
EPS
$-13.81
EPS estimate
$-1.69
Net margin
-1,943.2%

EPS came in at -13.81 against a street estimate of -1.69 — a miss of 717.2%.

Key statistics

Market cap
$200.9M
Forward P/E
0.0
P/B
99.22
Book value
$0.44
EPS (TTM)
$-29.59
52-week high
$45.50
52-week low
$4.97
50-day MA
$28.07
200-day MA
$20.45
Beta
2.63

Analyst view

Analysts rate Cue Biopharma a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $88.00.

Shareholding

Insiders
9.44%
Institutions
22.80%

Largest institutional holders

FundStake
Bleichroeder LP5.10%
Driehaus Capital Management LLC4.02%
Vanguard Capital Management, LLC2.23%
Ikarian Capital, LLC1.44%
Polygon Management Ltd1.29%
StemPoint Capital LP0.92%
BlackRock Inc0.80%
ADAR1 Capital Management LLC0.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cue Biopharma — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.